Search research articles
Contact Us
Filters
Showing results (211-220 of 247) with videos related to
Page
of 25
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 6, 2011
The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers
Boris B Quednow, Ulrich Ettinger, Rainald Mössner, et al.
Brain : a Journal of Neurology
|
October 22, 2025
Memory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities
Rebecca C Coray, Vincent Beliveau, Josua Zimmermann, et al.
European Addiction Research
|
November 19, 2024
Words versus Strands: Reliability and Stability of Concordance Rates of Self-Reported and Hair-Analyzed Substance Use of Young Adults over Time
Clarissa Janousch, Lukas Eggenberger, Annekatrin Steinhoff, et al.
Neuroimage. Clinical
|
March 6, 2024
Conflict monitoring and emotional processing in 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine users - A comparative neurophysiological study
Antje Opitz, Josua Zimmermann, David M Cole, et al.
Alzheimer'S Research & Therapy
|
July 25, 2024
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression
Miriam Rabl, Leonardo Zullo, Piotr Lewczuk, et al.
Journal of Psychiatric Research
|
June 5, 2012
Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics
Anna Schuhmacher, Tim Becker, Dan Rujescu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
March 13, 2017
Neural underpinnings of prosexual effects induced by gamma-hydroxybutyrate in healthy male humans
Oliver G Bosch, Michael M Havranek, Andrea Baumberger, et al.
Research Square
|
April 2, 2024
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression
Miriam Rabl, Leonardo Zullo, Piotr Lewczuk, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 14, 2025
Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial
Francesco Bavato, Laura K Schnider, Dario A Dornbierer, et al.
The International Journal of Neuropsychopharmacology
|
February 13, 2013
Nicotine enhances antisaccade performance in schizophrenia patients and healthy controls
Nadine Petrovsky, Ulrich Ettinger, Boris B Quednow, et al.
Page
of 25
Search research articles
Search
Showing results (211-220 of 247) with videos related to
Sort By:
Page
of 25
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 6, 2011
The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers
Boris B Quednow, Ulrich Ettinger, Rainald Mössner, et al.
Brain : a Journal of Neurology
|
October 22, 2025
Memory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities
Rebecca C Coray, Vincent Beliveau, Josua Zimmermann, et al.
European Addiction Research
|
November 19, 2024
Words versus Strands: Reliability and Stability of Concordance Rates of Self-Reported and Hair-Analyzed Substance Use of Young Adults over Time
Clarissa Janousch, Lukas Eggenberger, Annekatrin Steinhoff, et al.
Neuroimage. Clinical
|
March 6, 2024
Conflict monitoring and emotional processing in 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine users - A comparative neurophysiological study
Antje Opitz, Josua Zimmermann, David M Cole, et al.
Alzheimer'S Research & Therapy
|
July 25, 2024
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression
Miriam Rabl, Leonardo Zullo, Piotr Lewczuk, et al.
Journal of Psychiatric Research
|
June 5, 2012
Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics
Anna Schuhmacher, Tim Becker, Dan Rujescu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
March 13, 2017
Neural underpinnings of prosexual effects induced by gamma-hydroxybutyrate in healthy male humans
Oliver G Bosch, Michael M Havranek, Andrea Baumberger, et al.
Research Square
|
April 2, 2024
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression
Miriam Rabl, Leonardo Zullo, Piotr Lewczuk, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 14, 2025
Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial
Francesco Bavato, Laura K Schnider, Dario A Dornbierer, et al.
The International Journal of Neuropsychopharmacology
|
February 13, 2013
Nicotine enhances antisaccade performance in schizophrenia patients and healthy controls
Nadine Petrovsky, Ulrich Ettinger, Boris B Quednow, et al.
Page
of 25